Global RNAi for Therapeutic Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Highlights

Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, the global RNAi for Therapeutic market is projected to reach US$ 2218 million by 2028 from an estimated US$ 258.3 million in 2022, at a CAGR of 43.1% during 2023 and 2028.

Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.

US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.

In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.

The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global RNAi for Therapeutic market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the RNAi for Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

RXi Pharmaceuticals

Silence Therapeutics

Benitec Biopharma

miRagen Therapeutics

Sylentis

Gradalis

Sirnaomics

Silenseed

Product Type Insights

Global markets are presented by RNAi for Therapeutic type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the RNAi for Therapeutic are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

siRNA

miRNA

shRNA

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).

This report also outlines the market trends of each segment and consumer behaviors impacting the RNAi for Therapeutic market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the RNAi for Therapeutic market.

Cancer

Cardiovascular

HBV

Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue of each region and country for the period 2017-2028.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia-Pacific

China

Japan

South Korea

India

Southeast Asia

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the RNAi for Therapeutic market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNAi for Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of RNAi for Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the RNAi for Therapeutic industry.

This report helps stakeholders to gain insights into which regions to target globally.

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNAi for Therapeutic.

1.1 RNAi for Therapeutic Product Introduction

1.2 Market by Type

1.2.1 Global RNAi for Therapeutic Market Size Growth Rate by Type (2017 VS 2021 VS 2028)

1.2.2 siRNA

1.2.3 miRNA

1.2.4 shRNA

1.3 Market by Application

1.3.1 Global RNAi for Therapeutic Market Size Growth Rate by Application (2017 VS 2021 VS 2028)

1.3.2 Cancer

1.3.3 Cardiovascular

1.3.4 HBV

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

2.1 Global RNAi for Therapeutic Market Size Estimates and Forecasts

2.2 RNAi for Therapeutic Market Size by Region: 2022 Versus 2028

2.2.1 Global RNAi for Therapeutic Revenue by Region: 2017-2022

2.2.2 Global RNAi for Therapeutic Revenue Forecast by Region (2023-2028)

2.2.3 Global RNAi for Therapeutic Revenue Market Share by Region (2017-2028)

3.1 Global RNAi for Therapeutic Revenue by Company (2017-2022)

3.2 Global RNAi for Therapeutic Revenue Share by Company (2017-2022)

3.3 Competitive Landscape

3.3.1 Key RNAi for Therapeutic Companies around the World: Ranking by Revenue

3.3.2 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI) & (2017-2022)

3.3.3 Global RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.4 Global RNAi for Therapeutic Companies Headquarters & Product Type

3.4.1 RNAi for Therapeutic Companies Headquarters

3.4.2 Global RNAi for Therapeutic Companies Product & Service

3.4.3 Date of International Companies Enter into RNAi for Therapeutic Market

3.5 Global RNAi for Therapeutic Mergers & Acquisitions, Expansion Plans

4.1 Alnylam Pharmaceuticals

4.1.1 Alnylam Pharmaceuticals Corporation Information

4.1.2 Alnylam Pharmaceuticals Description, Business Overview

4.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Products Offered

4.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.1.5 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2021

4.1.6 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2021

4.1.7 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2021

4.1.8 Alnylam Pharmaceuticals Recent Developments

4.2 Arbutus Biopharma (Tekmira)

4.2.1 Arbutus Biopharma (Tekmira) Corporation Information

4.2.2 Arbutus Biopharma (Tekmira) Description, Business Overview

4.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products Offered

4.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.2.5 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue by Product in 2021

4.2.6 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue by Application in 2021

4.2.7 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue by Geographic Area in 2021

4.2.8 Arbutus Biopharma (Tekmira) Recent Developments

4.3 Arrowhead

4.3.1 Arrowhead Corporation Information

4.3.2 Arrowhead Description, Business Overview

4.3.3 Arrowhead RNAi for Therapeutic Products Offered

4.3.4 Arrowhead RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.3.5 Arrowhead RNAi for Therapeutic Revenue by Product in 2021

4.3.6 Arrowhead RNAi for Therapeutic Revenue by Application in 2021

4.3.7 Arrowhead RNAi for Therapeutic Revenue by Geographic Area in 2021

4.3.8 Arrowhead Recent Developments

4.4 Dicerna Pharmaceuticals

4.4.1 Dicerna Pharmaceuticals Corporation Information

4.4.2 Dicerna Pharmaceuticals Description, Business Overview

4.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Products Offered

4.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.4.5 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2021

4.4.6 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2021

4.4.7 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2021

4.4.8 Dicerna Pharmaceuticals Recent Developments

4.5 Mirna Therapeutics

4.5.1 Mirna Therapeutics Corporation Information

4.5.2 Mirna Therapeutics Description, Business Overview

4.5.3 Mirna Therapeutics RNAi for Therapeutic Products Offered

4.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.5.5 Mirna Therapeutics RNAi for Therapeutic Revenue by Product in 2021

4.5.6 Mirna Therapeutics RNAi for Therapeutic Revenue by Application in 2021

4.5.7 Mirna Therapeutics RNAi for Therapeutic Revenue by Geographic Area in 2021

4.5.8 Mirna Therapeutics Recent Developments

4.6 Quark Pharmaceuticals

4.6.1 Quark Pharmaceuticals Corporation Information

4.6.2 Quark Pharmaceuticals Description, Business Overview

4.6.3 Quark Pharmaceuticals RNAi for Therapeutic Products Offered

4.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.6.5 Quark Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2021

4.6.6 Quark Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2021

4.6.7 Quark Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2021

4.6.8 Quark Pharmaceuticals Recent Development

4.7 RXi Pharmaceuticals

4.7.1 RXi Pharmaceuticals Corporation Information

4.7.2 RXi Pharmaceuticals Description, Business Overview

4.7.3 RXi Pharmaceuticals RNAi for Therapeutic Products Offered

4.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.7.5 RXi Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2021

4.7.6 RXi Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2021

4.7.7 RXi Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2021

4.7.8 RXi Pharmaceuticals Recent Development

4.8 Silence Therapeutics

4.8.1 Silence Therapeutics Corporation Information

4.8.2 Silence Therapeutics Description, Business Overview

4.8.3 Silence Therapeutics RNAi for Therapeutic Products Offered

4.8.4 Silence Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.8.5 Silence Therapeutics RNAi for Therapeutic Revenue by Product in 2021

4.8.6 Silence Therapeutics RNAi for Therapeutic Revenue by Application in 2021

4.8.7 Silence Therapeutics RNAi for Therapeutic Revenue by Geographic Area in 2021

4.8.8 Silence Therapeutics Recent Development

4.9 Benitec Biopharma

4.9.1 Benitec Biopharma Corporation Information

4.9.2 Benitec Biopharma Description, Business Overview

4.9.3 Benitec Biopharma RNAi for Therapeutic Products Offered

4.9.4 Benitec Biopharma RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.9.5 Benitec Biopharma RNAi for Therapeutic Revenue by Product in 2021

4.9.6 Benitec Biopharma RNAi for Therapeutic Revenue by Application in 2021

4.9.7 Benitec Biopharma RNAi for Therapeutic Revenue by Geographic Area in 2021

4.9.8 Benitec Biopharma Recent Development

4.10 miRagen Therapeutics

4.10.1 miRagen Therapeutics Corporation Information

4.10.2 miRagen Therapeutics Description, Business Overview

4.10.3 miRagen Therapeutics RNAi for Therapeutic Products Offered

4.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.10.5 miRagen Therapeutics RNAi for Therapeutic Revenue by Product in 2021

4.10.6 miRagen Therapeutics RNAi for Therapeutic Revenue by Application in 2021

4.10.7 miRagen Therapeutics RNAi for Therapeutic Revenue by Geographic Area in 2021

4.10.8 miRagen Therapeutics Recent Development

4.11 Sylentis

4.11.1 Sylentis Corporation Information

4.11.2 Sylentis Description, Business Overview

4.11.3 Sylentis RNAi for Therapeutic Products Offered

4.11.4 Sylentis RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.11.5 Sylentis RNAi for Therapeutic Revenue by Product in 2021

4.11.6 Sylentis RNAi for Therapeutic Revenue by Application in 2021

4.11.7 Sylentis RNAi for Therapeutic Revenue by Geographic Area in 2021

4.11.8 Sylentis Recent Development

4.12 Gradalis

4.12.1 Gradalis Corporation Information

4.12.2 Gradalis Description, Business Overview

4.12.3 Gradalis RNAi for Therapeutic Products Offered

4.12.4 Gradalis RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.12.5 Gradalis RNAi for Therapeutic Revenue by Product in 2021

4.12.6 Gradalis RNAi for Therapeutic Revenue by Application in 2021

4.12.7 Gradalis RNAi for Therapeutic Revenue by Geographic Area in 2021

4.12.8 Gradalis Recent Development

4.13 Sirnaomics

4.13.1 Sirnaomics Corporation Information

4.13.2 Sirnaomics Description, Business Overview

4.13.3 Sirnaomics RNAi for Therapeutic Products Offered

4.13.4 Sirnaomics RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.13.5 Sirnaomics RNAi for Therapeutic Revenue by Product in 2021

4.13.6 Sirnaomics RNAi for Therapeutic Revenue by Application in 2021

4.13.7 Sirnaomics RNAi for Therapeutic Revenue by Geographic Area in 2021

4.13.8 Sirnaomics Recent Development

4.14 Silenseed

4.14.1 Silenseed Corporation Information

4.14.2 Silenseed Description, Business Overview

4.14.3 Silenseed RNAi for Therapeutic Products Offered

4.14.4 Silenseed RNAi for Therapeutic Revenue and Gross Margin (2017-2022)

4.14.5 Silenseed RNAi for Therapeutic Revenue by Product in 2021

4.14.6 Silenseed RNAi for Therapeutic Revenue by Application in 2021

4.14.7 Silenseed RNAi for Therapeutic Revenue by Geographic Area in 2021

4.14.8 Silenseed Recent Development

5.1 Global RNAi for Therapeutic Revenue by Type (2017-2022)

5.2 Global RNAi for Therapeutic Revenue Forecast by Type (2023-2028)

5.3 RNAi for Therapeutic Revenue Marke Share by Type (2017-2028)

6.1 Global RNAi for Therapeutic Revenue by Application (2017-2022)

6.2 Global RNAi for Therapeutic Revenue Forecast by Application (2023-2028)

6.3 RNAi for Therapeutic Revenue Market Share by Application (2017-2028)

7.1 North America RNAi for Therapeutic Market Size YoY Growth 2017-2028

7.2 North America RNAi for Therapeutic Market Facts & Figures by Country (2017-2028)

7.3 North America RNAi for Therapeutic Revenue by Type (2017-2022)

7.4 North America RNAi for Therapeutic Revenue by Application (2017-2022)

8.1 Asia-Pacific RNAi for Therapeutic Market Size YoY Growth 2017-2028

8.2 Asia-Pacific RNAi for Therapeutic Market Facts & Figures by Region (2017-2028)

8.3 Asia-Pacific RNAi for Therapeutic Revenue by Type (2017-2022)

8.4 Asia-Pacific RNAi for Therapeutic Revenue by Application (2017-2022)

9.1 Europe RNAi for Therapeutic Market Size YoY Growth 2017-2028

9.2 Europe RNAi for Therapeutic Market Facts & Figures by Country (2017-2028)

9.3 Europe RNAi for Therapeutic Revenue by Type (2017-2022)

9.4 Europe RNAi for Therapeutic Revenue by Application (2017-2022)

10.1 Latin America RNAi for Therapeutic Market Size YoY Growth 2017-2028

10.2 Latin America RNAi for Therapeutic Market Facts & Figures by Country (2017-2028)

10.3 Latin America RNAi for Therapeutic Revenue by Type (2017-2022)

10.4 Latin America RNAi for Therapeutic Revenue by Application (2017-2022)

11.1 Middle East and Africa RNAi for Therapeutic Market Size YoY Growth 2017-2028

11.2 Middle East and Africa RNAi for Therapeutic Market Facts & Figures by Country (2017-2028)

11.3 Middle East and Africa RNAi for Therapeutic Revenue by Type (2017-2022)

11.4 Middle East and Africa RNAi for Therapeutic Revenue by Application (2017-2022)

12.1 RNAi for Therapeutic Supply Chain Analysis

12.2 RNAi for Therapeutic Key Raw Materials and Upstream Suppliers

12.3 RNAi for Therapeutic Clients Analysis

12.4 RNAi for Therapeutic Sales Channel and Sales Model Analysis

12.4.1 RNAi for Therapeutic Distribution Channel Analysis: Indirect Sales VS Direct Sales

12.4.2 RNAi for Therapeutic Distribution Channel Analysis: Online Sales VS Offline Sales

12.4.3 RNAi for Therapeutic Distributors

13.1 RNAi for Therapeutic Industry Trends

13.2 RNAi for Therapeutic Market Drivers

13.3 RNAi for Therapeutic Market Challenges

13.4 RNAi for Therapeutic Market Restraints

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

List of Tables

    Table 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028

    Table 2. Major Companies of siRNA

    Table 3. Major Companies of miRNA

    Table 4. Major Companies of shRNA

    Table 5. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028

    Table 6. Global RNAi for Therapeutic Market Size by Region (US$ Million): 2022 VS 2028

    Table 7. Global RNAi for Therapeutic Revenue by Region (2017-2022) & (US$ Million)

    Table 8. Global RNAi for Therapeutic Revenue Forecast by Region (2023-2028) & (US$ Million)

    Table 9. RNAi for Therapeutic Revenue by Company (2017-2022) & (US$ Million)

    Table 10. RNAi for Therapeutic Revenue Share by Company (2017-2022)

    Table 11. Ranking of Global Top RNAi for Therapeutic Players by Revenue (US$ Million) in 2021

    Table 12. Global RNAi for Therapeutic Companies Market Concentration Ratio (CR5 and HHI) & (2017-2022)

    Table 13. Global RNAi for Therapeutic by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2021)

    Table 14. Global RNAi for Therapeutic Companies Headquarters

    Table 15. Global RNAi for Therapeutic Companies Product & Service

    Table 16. Date of International Companies Enter into RNAi for Therapeutic Market

    Table 17. Global RNAi for Therapeutic Mergers & Acquisitions, Expansion Plans

    Table 18. Alnylam Pharmaceuticals Corporation Information

    Table 19. Alnylam Pharmaceuticals Description and Business Overview

    Table 20. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 21. Alnylam Pharmaceuticals RNAi for Therapeutic Product

    Table 22. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 23. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 24. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 25. Alnylam Pharmaceuticals Recent Development

    Table 26. Arbutus Biopharma (Tekmira) Corporation Information

    Table 27. Arbutus Biopharma (Tekmira) Description and Business Overview

    Table 28. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 29. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product

    Table 30. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 31. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 32. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 33. Arbutus Biopharma (Tekmira) Recent Development

    Table 34. Arrowhead Corporation Information

    Table 35. Arrowhead Description and Business Overview

    Table 36. Arrowhead RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 37. Arrowhead RNAi for Therapeutic Product

    Table 38. Arrowhead RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 39. Arrowhead RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 40. Arrowhead RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 41. Arrowhead Recent Development

    Table 42. Dicerna Pharmaceuticals Corporation Information

    Table 43. Dicerna Pharmaceuticals Description and Business Overview

    Table 44. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 45. Dicerna Pharmaceuticals RNAi for Therapeutic Product

    Table 46. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 47. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 48. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 49. Dicerna Pharmaceuticals Recent Development

    Table 50. Mirna Therapeutics Corporation Information

    Table 51. Mirna Therapeutics Description and Business Overview

    Table 52. Mirna Therapeutics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 53. Mirna Therapeutics RNAi for Therapeutic Product

    Table 54. Mirna Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 55. Mirna Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 56. Mirna Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 57. Mirna Therapeutics Recent Development

    Table 58. Quark Pharmaceuticals Corporation Information

    Table 59. Quark Pharmaceuticals Description and Business Overview

    Table 60. Quark Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 61. Quark Pharmaceuticals RNAi for Therapeutic Product

    Table 62. Quark Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 63. Quark Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 64. Quark Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 65. RXi Pharmaceuticals Corporation Information

    Table 66. RXi Pharmaceuticals Description and Business Overview

    Table 67. RXi Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 68. RXi Pharmaceuticals RNAi for Therapeutic Product

    Table 69. RXi Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 70. RXi Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 71. RXi Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 72. Silence Therapeutics Corporation Information

    Table 73. Silence Therapeutics Description and Business Overview

    Table 74. Silence Therapeutics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 75. Silence Therapeutics RNAi for Therapeutic Product

    Table 76. Silence Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 77. Silence Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 78. Silence Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 79. Benitec Biopharma Corporation Information

    Table 80. Benitec Biopharma Description and Business Overview

    Table 81. Benitec Biopharma RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 82. Benitec Biopharma RNAi for Therapeutic Product

    Table 83. Benitec Biopharma RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 84. Benitec Biopharma RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 85. Benitec Biopharma RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 86. miRagen Therapeutics Corporation Information

    Table 87. miRagen Therapeutics Description and Business Overview

    Table 88. miRagen Therapeutics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 89. miRagen Therapeutics RNAi for Therapeutic Product

    Table 90. miRagen Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 91. miRagen Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 92. miRagen Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 93. Sylentis Corporation Information

    Table 94. Sylentis Description and Business Overview

    Table 95. Sylentis RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 96. Sylentis RNAi for Therapeutic Product

    Table 97. Sylentis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 98. Sylentis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 99. Sylentis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 100. Gradalis Corporation Information

    Table 101. Gradalis Description and Business Overview

    Table 102. Gradalis RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 103. Gradalis RNAi for Therapeutic Product

    Table 104. Gradalis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 105. Gradalis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 106. Gradalis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 107. Sirnaomics Corporation Information

    Table 108. Sirnaomics Description and Business Overview

    Table 109. Sirnaomics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 110. Sirnaomics RNAi for Therapeutic Product

    Table 111. Sirnaomics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 112. Sirnaomics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 113. Sirnaomics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 114. Silenseed Corporation Information

    Table 115. Silenseed Description and Business Overview

    Table 116. Silenseed RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)

    Table 117. Silenseed RNAi for Therapeutic Product

    Table 118. Silenseed RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021

    Table 119. Silenseed RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021

    Table 120. Silenseed RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021

    Table 121. Global RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)

    Table 122. Global RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)

    Table 123. Global RNAi for Therapeutic Revenue Forecast by Application (2023-2028) & (US$ Million)

    Table 124. North America RNAi for Therapeutic Revenue by Country (2017-2022) & (US$ Million)

    Table 125. North America RNAi for Therapeutic Revenue by Country (2023-2028) & (US$ Million)

    Table 126. North America RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)

    Table 127. North America RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)

    Table 128. Asia-Pacific RNAi for Therapeutic Revenue by Region (2017-2028) & (US$ Million)

    Table 129. Asia-Pacific RNAi for Therapeutic Revenue by Region (2023-2028) & (US$ Million)

    Table 130. Asia-Pacific RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)

    Table 131. Asia-Pacific RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)

    Table 132. Europe RNAi for Therapeutic Revenue by Country (2017-2022) & (US$ Million)

    Table 133. Europe RNAi for Therapeutic Revenue by Country (2023-2028) & (US$ Million)

    Table 134. Europe RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)

    Table 135. Europe RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)

    Table 136. Latin America RNAi for Therapeutic Revenue by Country (2017-2022) & (US$ Million)

    Table 137. Latin America RNAi for Therapeutic Revenue by Country (2023-2028) & (US$ Million)

    Table 138. Latin America RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)

    Table 139. Latin America RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)

    Table 140. Middle East and Africa RNAi for Therapeutic Revenue by Country (2017-2022) & (US$ Million)

    Table 141. Middle East and Africa RNAi for Therapeutic Revenue by Country (2023-2028) & (US$ Million)

    Table 142. Middle East and Africa RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)

    Table 143. Middle East and Africa RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)

    Table 144. RNAi for Therapeutic Key Raw Materials, Industry Status and Trend

    Table 145. RNAi for Therapeutic Key Raw Materials and Upstream Suppliers

    Table 146. RNAi for Therapeutic Clients Status and Trend

    Table 147. RNAi for Therapeutic Typical Clients

    Table 148. RNAi for Therapeutic Distributors

    Table 149. RNAi for Therapeutic Market Trends

    Table 150. RNAi for Therapeutic Market Drivers

    Table 151. RNAi for Therapeutic Market Challenges

    Table 152. RNAi for Therapeutic Market Restraints

    Table 153. Research Programs/Design for This Report

    Table 154. Key Data Information from Secondary Sources

    Table 155. Key Data Information from Primary Sources

List of Figures

    Figure 1. RNAi for Therapeutic Product Picture

    Figure 2. Global RNAi for Therapeutic Revenue Market Share by Type in 2021 & 2028

    Figure 3. siRNA Product Picture

    Figure 4. miRNA Product Picture

    Figure 5. shRNA Product Picture

    Figure 6. Global RNAi for Therapeutic Revenue Market Share by Application in 2021 & 2028

    Figure 7. Cancer

    Figure 8. Cardiovascular

    Figure 9. HBV

    Figure 10. Others

    Figure 11. RNAi for Therapeutic Report Years Considered

    Figure 12. Global RNAi for Therapeutic Revenue, (US$ Million), 2017 VS 2021 VS 2028

    Figure 13. Global RNAi for Therapeutic Market Size 2017-2028 (US$ Million)

    Figure 14. Global RNAi for Therapeutic Market Size Market Share by Region: 2022 Versus 2028

    Figure 15. Global RNAi for Therapeutic Revenue Market Share by Region (2017-2028)

    Figure 16. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021

    Figure 17. Global RNAi for Therapeutic Revenue Market Share Forecast by Type (2017-2028)

    Figure 18. Global RNAi for Therapeutic Revenue Market Share Forecast by Application (2017-2028)

    Figure 19. North America RNAi for Therapeutic Revenue 2017-2028 (US$ Million)

    Figure 20. North America RNAi for Therapeutic Revenue Market Share by Type (2017-2022)

    Figure 21. North America RNAi for Therapeutic Revenue Market Share by Application (2017-2022)

    Figure 22. Asia-Pacific RNAi for Therapeutic Revenue 2017-2028 (US$ Million)

    Figure 23. Asia-Pacific RNAi for Therapeutic Revenue Market Share by Region (2017-2028)

    Figure 24. Asia-Pacific RNAi for Therapeutic Revenue Market Share by Type (2017-2022)

    Figure 25. Asia-Pacific RNAi for Therapeutic Revenue Market Share by Application (2017-2022)

    Figure 26. Europe RNAi for Therapeutic Revenue Growth Rate 2017-2028 (US$ Million)

    Figure 27. Europe RNAi for Therapeutic Revenue Market Share by Country (2017-2028)

    Figure 28. Europe RNAi for Therapeutic Revenue Market Share by Type (2017-2022)

    Figure 29. Europe RNAi for Therapeutic Revenue Market Share by Application (2017-2022)

    Figure 30. Latin America RNAi for Therapeutic Revenue Growth Rate 2017-2028 (US$ Million)

    Figure 31. Latin America RNAi for Therapeutic Revenue Market Share by Country (2017-2022)

    Figure 32. Latin America RNAi for Therapeutic Revenue Market Share by Type (2017-2022)

    Figure 33. Latin America RNAi for Therapeutic Revenue Market Share by Application (2017-2022)

    Figure 34. Middle East and Africa RNAi for Therapeutic Revenue Growth Rate 2017-2028 (US$ Million)

    Figure 35. Middle East and Africa RNAi for Therapeutic Revenue Market Share by Country (2017-2028)

    Figure 36. Middle East and Africa RNAi for Therapeutic Revenue Market Share by Type (2017-2022)

    Figure 37. Middle East and Africa RNAi for Therapeutic Revenue Market Share by Application (2017-2022)

    Figure 38. RNAi for Therapeutic Supply Chain (Upstream and Downstream Market)

    Figure 39. Global Production Market Share of RNAi for Therapeutic Raw Materials by Region in 2021

    Figure 40. RNAi for Therapeutic Distribution Channels

    Figure 41. Global RNAi for Therapeutic Percentage 2017-2028: Indirect Sales VS Direct Sales

    Figure 42. Global RNAi for Therapeutic Percentage 2017-2028: Online Sales VS Offline Sales

    Figure 43. Bottom-up and Top-down Approaches for This Report

    Figure 44. Data Triangulation

    Figure 45. Key Executives Interviewed